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Association of parvovirus B19 infection with idiopathic collaps- Collapsing glomerulopathy (CG) is a distinct variant
ing glomerulopathy. of focal and segmental glomerulosclerosis (FSGS) that
Background. Collapsing glomerulopathy (CG), a disorder may occur as an idiopathic process or in patients infectedwith severe glomerular and tubular involvement, occurs either
with human immunodeficiency virus (HIV) known asas an idiopathic lesion or in some patients with human immuno-
HIV-associated nephropathy (HIVAN) [1–5]. Patientsdeficiency virus (HIV) infection known as HIV-associated ne-
phropathy (HIVAN). We previously reported a renal trans- with idiopathic CG and HIVAN share similar clinical and
plant recipient with de novo CG and red cell aplasia in pathologic features with most cases rapidly progressing
association with persistent parvovirus B19 (PVB19) infection. to end-stage renal disease (ESRD) [1, 4]. The etiologyThis prompted us to look for an association between PVB19
and pathogenesis of these disorders are unknown. Thereinfection and CG.
is evidence suggesting that HIV infection of renal epithe-Methods. DNA from archived biopsies of patients with CG
was analyzed for PVB19 by polymerase chain reaction (PCR). lial cells may be responsible for inducing HIVAN [6–8].
Results were compared with HIVAN, idiopathic focal segmen- Recently, we reported de novo CG in an HIV-negative
tal glomerulosclerosis (FSGS), and controls. In situ hybridiza- renal transplant recipient with chronic PVB19 infectiontion (ISH) was done to localize PVB19 in renal biopsies. Pe-
[9]. PVB19 DNA was detected in blood and renal tissue.ripheral blood specimens of patients with CG, HIV infection,
These findings in a patient with ESRD secondary to auto-healthy controls, and randomly selected hospitalized patients
(sick controls) were also analyzed for PVB19. somal dominant polycystic disease suggested a causal
Results. PVB19 DNA was detected in renal biopsies of 18 relationship between PVB19 infection and CG.
out of 23 (78.3%) patients with CG, 3 out of 19 (15.8%) with PVB19 infection is common in the general population,HIVAN, 6 out of 27 (22.2%) with FSGS, and 7 out of 27
with increasing prevalence with age [10]. Although most(25.9%) controls (P , 0.01, CG vs. HIVAN, FSGS, and con-
infections are minimally symptomatic, aplastic anemiatrols). PVB19 was detected in peripheral blood of 7 out of 8
(87.5%) CG patients, 3 out of 22 (13.6%) with HIV infection, can occur in patients with sickle cell disease and other
4 out of 133 (3%) healthy controls, and 2 out of 50 (4%) sick chronic hemolytic disorders infected with PVB19 [11, 12].
controls (P , 0.001, CG vs. HIV infected, healthy, and sick Infection may become chronic in immunosuppressed in-controls). PVB19 was identified in glomerular parietal and
dividuals and cause pure red cell aplasia [13, 14]. Focalvisceral epithelial and tubular cells by ISH.
segmental glomerulonephritis and FSGS were describedConclusions. The significantly higher prevalence of PVB19
DNA in renal biopsies and peripheral blood of CG patients in children with sickle cell disease and PVB19 infection
suggests a specific association between PVB19 infection and [15, 16]. Recently, a greater prevalence of PVB19 DNA
CG. In susceptible individuals, renal epithelial cell infection was reported in renal biopsies of patients with idiopathicwith PVB19 may induce CG.
and collapsing forms of FSGS as compared with those
with membranous nephropathy and minimal change dis-
ease [17]. Based on our observations [9] and those of
others [15–17], we speculated that PVB19 infection
1 Both authors contributed equally to this paper might induce CG or other form of glomerulopathies in
susceptible individuals. To test this hypothesis, we stud-Key words: focal segmental glomerulosclerosis, human immunodefi-
ciency virus, red cell aplasia, end-stage renal disease. ied archived renal biopsies of patients with CG, HIVAN,
and FSGS, and controls for PVB19 DNA by polymeraseReceived for publication September 29, 2000
chain reaction (PCR). Additionally, we prospectively an-and in revised form January 5, 2001
Accepted for publication January 10, 2001 alyzed peripheral blood specimens of patients with CG,
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and randomly selected hospitalized patients (sick con- Gene amplification by PCR
trols) for PVB19. Table 1 shows the sequence of primers, product size,
and number of cycles used for PCR. DNA extracted from
tissue and blood was analyzed for insulin and b-globin,
METHODS respectively, to assess its adequacy.
Renal biopsy specimens PVB19-PCR. Nested PCR was used to detect PVB19
DNA. Two sets of primers targeted at two separateRenal biopsies accessioned in the renal pathology divi-
genes, one encoding nonstructural (PVB19-a) and thesion at Cedars-Sinai Medical Center (Los Angeles, CA,
other nucleocapsid (PVB19-b) region of PVB19, wereUSA) between January 1994 to March 1999 were uti-
used (Table 1).lized. The specimens were processed in the standard
(a) “Outer” PCR. Five microliters or 1 mg of DNAfashion and evaluated by light, immunofluorescence and
solution in TE extracted from the renal biopsy and blood,electron microscopies [18]. Frozen renal tissue from pa-
respectively, or 5 mL of serum were mixed with 20 mLtients with CG (N 5 23), HIVAN (N 5 19), idiopathic
of mixture containing 5.0 mmol/L of magnesium chlo-FSGS (N 5 27), and controls (normal biopsies of patients
ride, 0.2 mmol/L dNTP (Boeringer Mannheim, Indianap-
with hematuria, minimal change disease, thin basement
olis, IN, USA), 0.1 mmol/L each of upstream and down-
membrane disease, and normal portion of nephrectomies stream primers (Oligos ETC., Wilsonville, OR, USA),
for renal cell carcinoma, N 5 27) were examined for 1 unit of Amplitaq (Perkin Elmer Cetus, Norwalk, CT,
PVB19 DNA. USA), 1 3 PCR buffer (Perkin Elmer), and sterile water
(Life Technologies, Gaithersburg, MD, USA). PCR was
Peripheral blood specimens performed in a thermal cycler (Perkin-Elmer) pro-
Peripheral blood specimens in ethylenediaminetetra- grammed for two minutes at 958C followed by a cycle
acetic acid (EDTA) were collected prospectively from of 30 seconds at 958C, 30 seconds at 608C, and 30 seconds
8 patients with CG, 22 patients with HIV infection, 13 at 728C for 30 cycles, followed by cooling to 48C.
controls, and 50 sick controls. Renal biopsy specimens (b) “Nested” PCR. Four microliters of outer PCR
were available for PVB19 DNA analysis in all patients product were mixed with 21 mL of mixture containing
2.0 mmol/L of magnesium, 0.5 mmol/L each of upstreamwith CG, whereas none with HIV infection, controls, or
and downstream primers, and the remaining reagents insick controls had renal biopsies. Leukocyte pellets were
same amount as in the outer PCR and amplified for 25prepared by lysing erythrocytes with ammonium chlo-
cycles. A known positive control (PVB19 DNA) and aride and ammonium bicarbonate and submitted for DNA
negative control (water) were included. The PCR prod-extraction [19]. Additionally, serum specimens were ob-
ucts were run through 5% polyacrylamide gel to separatetained from 120 blood bank donors.
and size DNA fragments. The gel was stained with ethid-
ium bromide and analyzed under ultraviolet light.DNA extraction
Insulin-polymerase chain reaction. Insulin-PCR con-DNA was extracted from renal tissue and leukocyte
ditions were same as that for PVB19 except for the fol-pellets using QIAamp tissues kit (Qiagen Inc., Chats-
lowing differences. In the outer PCR, the magnesium chlo-worth, CA, USA). Briefly, proteinase K stock solution
ride concentration was 3.0 mmol/L, and upstream and
was added to five or six (4 m thick) renal tissue sections
downstream primers were 0.1 mmol/L each. Amplification
or to leukocyte pellets to break off all cell membranes was done for 15 cycles. In the nested PCR, 2 mL of outer
and release nucleic acid in the solution. DNA was precipi- PCR product were mixed with 23 mL of mixture con-
tated by adding 100% ethanol. Five micrograms of t-RNA taining 3.0 mmol/L magnesium chloride and 0.7 mmol/L
were added to facilitate DNA precipitation from tissue each of upstream and downstream primers and were
sections before adding ethanol. This mixture was then amplified for 20 cycles.
passed through spin columns and filtrate discarded. Spin b-Globin-polymerase chain reaction. Single PCR was
columns were washed twice. DNA bound to spin col- used for b-globin as previously published [20].
umns was eluted with 50 mL of Tris-EDTA (TE; 1 mol/L, All possible precautions were taken to avoid cross
0.1 mmol/L) for tissue sections and 100 mL of TE for contamination while cutting the sections, at the time of
leukocyte pellets. The DNA concentration was calcu- DNA extraction, and during PCR procedures. Cryostat
lated by measuring optical density at 260 nm in solutions was cleaned meticulously with bleach after cutting sec-
obtained from leukocyte pellets. DNA thus obtained was tions from each specimen. Designated pipettes and fil-
stored at 2808C until analyzed. One microgram of DNA tered pipette tips were used for DNA extraction and
from leukocyte pellets or 5 mL DNA solution from tissue PCR. All reagents were aliquoted. Different laboratory
benches were used for pre- and post-PCR procedures.sections were submitted for PCR.
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Table 1. Primers and experimental conditions for polymerase chain reaction (PCR)
Product Amplification
Target gene Primer sequence bp cycles Reference
PV B19-aa
Outer 59-AAT ACA CTG TGG TTT TAT GGG CCG 284 30 [37]
39-CCA TTG CTG GTT ATA ACC ACA GGT
Nest 59-AAT GAA AAC TTT CCA TTT AAT GAT GTAG 103 25
39-CTA AAA TGG CTT TTG CAG CTT CTAC
PVB19-bb
Outer 59-AAG TTT GCC GGA AGT TCC CG 403 30 [38]
39-AGC ATC AGG AGC TAT ACT TCC
Nest 59-CCC AAG CAT GAC TTC AG 279 25
39-TCT AAA TAT CTC CAT GG
Insulinc
Outer 59-GGA CAG GCT GCA TCA GAA GAG G 391 15
39-GGT CTT GGG TGT GTA GAA GAA GC
Nest 59-ATC AAG CAG GTC TGT TCC AAG G 333 20
39-CAC ACT AGG TAG AGA GCT TCC A
b-globin 59-TTG CTA ATC ATG TTC ATA CC 184 35 [20]
39-AGC AAG AAA GCG AGC TTA GT
a PV B19-a and b PVB19-b, targeted at genes encoding nonstructural and nucleocapsid regions, respectively
c Insulin, designed in our laboratory
The PCR amplification was performed twice on each night at 48C. Slides were counterstained with methyl
DNA extract. In 12 out of 33 (36%) biopsy specimens green. Bone marrow slides from two fetuses with PVB19
that were positive for PVB19 DNA, repeat biopsy sec- induced hydrops fetalis were used as positive controls.
tions were obtained for DNA extraction and subsequent Negative controls included pretreatment with DNase,
PCR analysis to confirm results. These 12 specimens and substitution of PVB19 probe with cytomegalovirus,
were obtained from those in which enough biopsy mate- and Epstein-Barr virus probes.
rial was available.
Ultrastructural examination of renal specimens
In situ hybridization for PVB19
for PVB19
Biotinylated probe for PVB19. Plasmid containing
Three biopsies with CG and positive in situ hybridiza-PVB19 DNA was the courtesy of Dr. P. Tattersall [21].
tion (ISH) for PVB19 were selected for ultrastructuralThe plasmid was transformed in Escherichia coli, INVaF
evaluation. Three to five glomeruli with large numberscells (Invitrogen Co., San Diego, CA, USA). After colo-
of vacuolated atypical visceral epithelial cells were exam-nies were cultured, the plasmid was isolated by miniprep
ined for PVB19 virions.DNA purification system (Promega, Madison, WI, USA).
The plasmid was confirmed by fragment size obtained
Clinical data and statistical analysisafter digestion with restriction enzyme and by PCR. The
digested plasmid was separated on an agarose gel, and Clinical information was obtained by retrospective
a 3.9 kb fragment was excised and isolated using quick chart review. Mann–Whitney U test was used for statisti-
gel extraction kit (Qiagen). PVB19 DNA thus obtained cal comparison of ages between various groups. Chi-
was biotinylated using BioPrime DNA labeling system square test was used for the remaining comparisons.
(GIBCO BRL, Grand Island, NY, USA).
In situ hybridization. A biotinylated probe was used
for in situ detection of PVB19 DNA by the Enzo patho- RESULTS
Gene DNA probe assay protocol (Enzo Diagnostics,
Demographics and clinical information are shown inInc., Farmingdale, NY, USA) [22]. Slides containing one
Table 2. The mean age of CG patients was comparableto three sections were deparaffinized, dehydrated, and
to HIVAN, FSGS, and controls. There were more femalepostfixed in neutral-buffered formalin for 20 minutes.
patients in CG compared with HIVAN and FSGS. CGAfter rinsing, slides were treated with pronase for three
and HIVAN patients were predominantly African Ameri-minutes and were rinsed and subsequently fixed in para-
cans. Hypertension, hematuria, proteinuria, and nephroticformaldehyde for five minutes. After treatment with gly-
syndrome were observed in all groups. Elevated creati-cine and dehydration, the biotin-labeled probe was ap-
nine and anemia were more frequent in CG and HIVANplied overnight. Streptavidin alkaline phosphatase (BRL)
was added followed by NBT/BICP developer used over- patients.
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Table 2. Demographics and clinical information
CG HIVAN FSGS Control
Number of patients 23 19 27 27
Age (mean6SD) 39.7617 36.6612 45.7623 30614
Sex M:F 9:14a,b 14:5 18:9 11:16
Race
African Americans % 16 (72.7)b,c 17 (94.1) 2 (7.4) 3 (11.1)
Caucasian/Hispanic/Other 2/3/2 1/0/1 16/7/2 12/9/3
Clinical features %
Proteinuria 23 (100) 19 (100) 27 (100) N/A
Nephrotic syndrome 17 (73.9) 15 (78.9) 17 (62.9)
Hematuria 18 (78.2) 15 (78.9) 14 (51.8)
Hypertension 14 (60.8) 10 (52.6) 10 (37)
Elevated creatinine 22 (95.6)b 18 (94.7) 13 (48.1)
Anemia 8 (34.8)b 12 (63.1) 2 (7.4)
Abbreviations are: CG, collapsing glomerulopathy; HIVAN, HIV-associated nephropathy; FSGS, focal segmental glomerulosclersis.
a,b,cP , 0.05, CG vs. HIVAN, CG vs. FSGS and CG vs. control, respectively
Table 4. PVB19 DNA detection in the peripheral blood by PCRTable 3. PVB19 DNA detection in renal specimens by PCR
Sample PVB19 DNA (1) Sample PVB19 DNA (1)
Diagnosis N N (%)Diagnosis N N (%)
CG 23 18 (78.3)a CG 8c 7 (87.5)a
HIV (1) 22 3 (13.7)HIVAN 19 3 (15.7)
FSGS 27 6 (22.2) Controlsb 133 4 (3)
Sick controls 50 2 (4)Controls 27 7 (25.9)
aP , 0.001, CG vs. HIV (1), controls and sick controlsaP , 0.01, CG vs. HIVAN, FSGS and controls
b Controls included leukocytes from 13 and serum specimens from 120 healthy
individuals
c PVB19 DNA results in the blood specimens of these patients corresponded
with the biopsy results
PVB19 DNA detection in renal biopsy specimens
Ninety-six specimens were available, 23 CG, 19
HIVAN, 27 FSGS, and 27 controls. Insulin gene was de- PVB19 DNA localization in renal biopsies
tected in all of them. PVB19 DNA was detected in 18 out
Of 13 biopsy specimens (5 CG, 4 FSGS, 3 HIVAN,
of 23 CG (78.3%), which was significantly higher (P , and 1 control) positive for PVB19 DNA by PCR, PVB19
0.01) than HIVAN (15.8%), FSGS (22.2%), and controls was detected in 10 by ISH (Table 5). PVB19 DNA was
(25.9%). No significant differences were observed be- present in some glomerular visceral epithelial cells in
tween HIVAN, FSGS, and controls (Table 3). PVB19 nine, parietal epithelial cells in eight, and tubular cells
DNA was detected in 12 of 16 African American patients in seven (Fig. 1 A, C, and F). In positive CG and HIVAN
(75%) and 6 of 7 (85.7%) in non–African Americans cases, all visceral epithelial cells containing PVB19 ge-
with CG (P 5 NS). There were only two black patients nome were morphologically abnormal, with the percent-
in the FSGS group, and PVB19 DNA was detected in age of positive cells usually ranging from 10 to 40% and
both as compared with 4 out of 25 nonblacks (16%). in occasional case as high as 80% for each glomerulus
(Fig. 1C). Positive parietal cells were morphologically
PVB19 DNA detection in the peripheral blood normal or had expanded cytoplasm, which contained
b-Globin was detected in all samples. PVB19 DNA small vacuoles (Fig. 1A), and were always in glomeruli
was detected in the peripheral blood of 7 out of 8 CG with at least segmental collapsing features. Positive epi-
patients (87.5%; Table 4), which was significantly higher thelial cells in FSGS glomeruli were infrequent and over-
(P , 0.001) than those with HIV infection (13.7%) and lay the sclerotic segments. Tubular epithelium containing
controls (3%), and sick controls (4%). PVB19 DNA the PVB19 genome was always in tubules of normal size,
results in blood of patients with CG exactly corre- usually without inflammation, and varied from one or
sponded with renal biopsy results. In two patients with two positive tubules to 30% involvement; microcystically
CG and blood samples obtained at monthly intervals, dilated tubules were virtually always negative. Localiza-
PVB19 DNA was identified until six and nine months tion of PVB19 to renal epithelium was identical in pa-
after the initial diagnosis. It could no longer be detected tients with CG, FSGS, and HIVAN, although staining
following treatment with intravenous immune globulin was somewhat less apparent in the latter two groups.
PVB19 DNA was detected primarily in the cytoplasmand significant reduction in immunosuppression.
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Table 5. Number of cases with PVB19 detected by in situ hybridization
PVB19 DNA 1 PVB19 DNA 2
Diagnosis PCR In situ PCR In situ PVB19 DNA localization
CG (5) (5) (4) (4) PEC (4), VEC (4), TC (3), AEC (1)
HIVAN (3) (2) (2) (2) PEC (2), VEC (2), TC (1)
FSGS (4) (3) (4) (4) PEC (2), VEC (3), TC (3)
Controls (1) (0) (3) (0)
Abbreviations are: PEC, parietal epithelial cells; VEC, visceral epithelial cells; TC, tubular cells; AEC, arterial endothelial cells.
Fig. 1. Parvovirus B19 (PVB19) in situ hy-
bridization of renal biopsy from patient with
collapsing glomerulopathy (CG) and PVB19
(1) by polymerase chain reaction (PCR). Vi-
ral genome in (A) parietal epithelial cells
(arrow) of otherwise normal-appearing glo-
merulus; (C) enlarged glomerular epithelial
cell (arrow) overlying collapsed segment, and
adjacent parietal epithelium (arrowhead); (F)
tubular epithelial cell cytoplasm (arrows) with
weak staining of glomerular parietal epithe-
lium (arrowhead). (B and D) Compare with
periodic acid methanamine silver-stained sec-
tions. (E and G) Negative controls pretreated
with DNase. (H) Positive control showing
staining of early erythroid line cell (arrow) in
bone marrow from a PVB19 infected fetus.
Original magnification 3160.
of renal epithelial cells, but a perinuclear distribution DISCUSSION
cannot be excluded (Fig. 1C). Of 13 specimens negative In many patients with CG, a history of preceding or
for PVB19 by PCR, none were positive by in situ. In the concurrent systemic illness suggests an infectious etiol-
bone marrow of fetuses with hydrops fetalis, intense ogy [1, 2], but no specific infections have been identified.
staining for PVB19 was seen in the nuclei of early eryth-
This report demonstrates an association between PVB19roid cells (Fig. 1H).
infection and CG. PVB19 DNA was detected in 78% of
Electron microscopy renal biopsies from patients with CG, a number signifi-
cantly greater than controls, HIVAN, and FSGS. Al-Electron microscopy of three biopsies positive by ISH
though patients with CG and HIVAN shared similarfor PVB19 did not reveal viral particles in the cytoplasm
or nuclei of any cells. demographic, clinical, and many pathologic features, the
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prevalence of PVB19 was not increased in HIVAN, sug- express Gb 4 receptors rendering them susceptible to
PVB19 infection. Further studies are needed to identifygesting that PVB19 infection is specific to the subgroup
of CG. This is further supported by isolation of PVB19 renal cells capable of expressing Gb 4 receptor.
Parvovirus B19 is localized primarily to the nucleus ofDNA from the peripheral blood of 87% CG patients
compared with 13.7% with HIV infection, 3% of healthy infected erythrocyte pronormoblasts [27]. The apparent
cytoplasmic distribution of PVB19 in the renal epithelialcontrols, and 4% of sick controls. There was an increase
in frequency of PVB19 detection from the peripheral cells by in situ may be related to the unique characteris-
tics of these cells. It has been shown that uptake of theblood of HIV infected individuals as compared with con-
trols (P , 0.05), but this was not associated with in- parvoviruses occurs irrespective of the host cell position
in the mitotic cycle, allowing parvoviruses to infect rest-creased PVB19 isolation in renal biopsies from HIVAN
patients. ing and proliferating cells with equal efficiency [28, 29].
Whether PVB19 goes through a productive phase andAn association of PVB19 infection with focal prolifer-
ative glomerulonephritis and FSGS was described in initiates pathogenic changes in these renal epithelial cells
cannot be addressed by this study. However, the cyto-seven patients with sickle cell anemia and PVB19-in-
duced aplastic crisis [16]. However, our close review of plasmic changes observed in these cells positive for
PVB19 suggests the pathogenecity of the virus.the published biopsy photographs suggests the lesion to
be CG. Several investigators have reported an increased The pathogenesis of CG remains elusive. The charac-
teristic glomerular changes include increased size andincidence of de novo CG in transplant recipients in re-
cent years [23, 24]. This may be due to increased use of number of glomerular visceral epithelial cells that con-
tain cytoplasmic vacuoles, protein reabsorption droplets,powerful immunosuppression and therefore an increased
incidence of viral infections, but association with specific and occasional mitotic figures [30], suggesting these cells
play a prominent role in disease development [31]. Re-viral agents has not been sought. Based on our data, we
speculate that CG in transplant recipients may be re- cently, it has been suggested that parietal epithelial cells
also are involved in this process [32]. We detected PVB19lated, at least in part, to PVB19 infection.
While this manuscript was in preparation, Tanawat- genome in both parietal and visceral epithelial cells, the
cells implicated in the pathogenesis of CG, suggestingtancharoen et al reported their findings in a similar study
[17]. They found PVB19 DNA in 90% of patients with that both cell types interact with the virus. In HIVAN,
HIV has been identified in similar locations by ISHidiopathic CG, a number similar to that of ours. How-
ever, they detected PVB19 in 80% with idiopathic FSGS [33, 34]. Our observations and these studies suggest that
renal epithelial cell infection by PVB19 or HIV mayand 54% controls in contrast to 22 and 26%, respectively,
in our series. The reason for these discrepancies is unclear initiate CG or HIVAN, respectively.
Since PVB19 infection is common in the general popu-and may be related to regional and ethnic variations. A
study of PVB19 DNA in renal biopsies of HIVAN pa- lation but CG is a rare entity, we speculate that the renal
response to PVB19 depends on several viral, host, ortients as well as the information on prevalence of PVB19
DNA in the peripheral blood of CG and control popula- other cofactors. The prevalence of PVB19 DNA in 26%
biopsy specimens of control population by PCR alsotion from their region would have been helpful to explain
some of these differences. suggests that an additional factor/insult is needed to
cause pathogenic effects. Of eight CG patients studiedIn this study, viral genome was identified within renal
epithelial cells in 10 of 13 biopsy specimens positive prospectively in this series, seven had PVB19 DNA de-
tected in the blood at the time of renal biopsy. In twofor PVB19 by PCR (Table 5). This confirmed the PCR
findings and excluded the possibility that detection of patients, PVB19 was detected for six and nine months.
This suggests that some patients have specific immunePVB19 in renal tissue was due to contamination by
PVB19-positive blood or cross contamination by other defects resulting in an inability to generate cellular and
humoral immune responses required to clear the virus,positive samples. The inability to detect PVB19 by ISH
in the remaining three specimens may be due to low and leads to viral persistence with presumed increased
infectivity and additional clinical and/or disease manifes-viral copy number and focal infection; these features
may also explain the lack of virion identification ultra- tations. African ancestry appears to be an important risk
factor, as CG and HIVAN occur predominantly in thisstructurally. Localization of PVB19 to glomerular pari-
etal and visceral and tubular epithelial cells demonstrates population [1, 4]. Recent data have shown that African
Americans are hyperproducers of transforming growththe capability of virus to infect renal epithelium. PVB19
binds to a globoside (Gb 4) receptor on erythrocytes factor-b, a cytokine associated with a profibrogenic pro-
file [35]. It is possible this patient cohort has an excessive[25]. Recently, Cooling, Koerner, and Naides demon-
strated Gb 4 receptors in several tissues, including human proliferative and sclerosing response to a viral insult
(HIV or PVB19). Alternatively, PVB19 receptor densitykidney [26]. Although specific intrarenal sites of this
receptor are unknown, it is possible that epithelial cells on erythrocytes and renal epithelium may be different
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8. Bruggeman LA, Dikman S, Meng C, et al: Nephropathy in humanin individuals with different genetic backgrounds. It is
immunodeficiency virus-1 transgenic mice is due to renal transgenepossible those lacking Gb 4 receptors cannot be infected expression. J Clin Invest 100:84–92, 1997
with PVB19 in the kidney, indicating individual variation 9. Moudgil A, Shidban H, Nast CC, et al: Parvovirus B19 infection-
related complications in renal transplant recipients: Treatment within susceptibility to PVB19 infection [36].
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of the PVB19 genome in renal tissue and peripheral parvovirus B19 in England and Wales. J Med Microbiol 25:151–153,
1988blood with CG. PVB19 infects renal epithelial cells and
11. Pattison JR, Jones SE, Hodgan J, et al: Parvovirus infection andmay initiate CG in susceptible individuals. However,
hypoplastic crisis in sickle cell anemia. Lancet 1:664–665, 1981most people with PVB19 infection do not have and likely 12. Belloy M, Morinet F, Blondin G, et al: Erythroid hypoplasia
will never develop CG. Further studies are needed to due to chronic infection with parvovirus B19. N Engl J Med
322:633–634, 1990identify factors rendering susceptibility to the develop-
13. Frickhofen N, Abcowitz JL, Safford M, et al: Persistent B19ment of CG, to identify renal cells that express PVB19
parvovirus infection in patients infected with human immunodefi-
receptors, to demonstrate pathogenic effects of the virus ciency virus type 1 (HIV-1): A treatable cause of anemia in AIDS.
Ann Intern Med 113:926–933, 1990on renal epithelium, and to understand defects in im-
14. Wong TY, Chan PK, Leung CB, et al: Parvovirus B19 infectionmune responses to PVB19 infection in CG patients.
causing red cell aplasia in renal transplantation on tacrolimus. AmThese would be critical to unraveling the pathogenesis J Kidney Dis 34:1132–1136, 1999
of PVB19 associated CG and for developing novel thera- 15. Markenson AL, Chandra M, Lewy JE, Miller DR: Sickle cell
anemia, the nephrotic syndrome and hypoplastic crisis in a sibship.peutic approaches to this disease.
Am J Med 64:719–723, 1978
16. Wierenga KJ, Pathison JR, Brink N, et al: Glomerulonephritis
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